Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.63 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.58 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11828505 | 0.98 | SIGMAR1 (0.70) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL6198442 | 0.95 | SIGMAR1 (0.69) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL10360724 | 0.88 | SLC18A3 (0.69) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL7259165 | 0.86 | SIGMAR1 (0.75) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL7382438 | 0.83 | SIGMAR1 (0.69) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL11241313 | 0.83 | SIGMAR1 (0.69) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL2097765 | 0.83 | SIGMAR1 (0.69) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL6591133 | 0.83 | SLC18A3 (0.78) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL256656 | 0.83 | DRD2 (0.78) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL7455681 | 0.83 | SIGMAR1 (0.55) | SIGMAR1MEN1TP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828352-B2 | Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR) | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-11-28 | — | — | US | disclosed |
| US-9828352-B2 | Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR) | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-11-28 | — | — | US | disclosed |
| US-9828352-B2 | Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR) | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-11-28 | — | — | US | disclosed |
| EP-3022179-B1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | FOND ST ITALIANO TECNOLOGIA (IT) | 2017-11-15 | — | — | EP | disclosed |
| EP-3022179-B1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | FOND ST ITALIANO TECNOLOGIA (IT) | 2017-11-15 | — | — | EP | disclosed |
| US-20160194296-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-07-07 | — | — | US | disclosed |
| US-20160194296-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-07-07 | — | — | US | disclosed |
| US-20160194296-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-07-07 | — | — | US | disclosed |
| EP-3022179-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | Fondazione Istituto Italiano Di Tecnologia (IT) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015007615-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-01-22 | — | — | WO | disclosed |
| EP-1044197-A2 | NEW PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | Klinge Pharma GmbH (DE) | 2000-10-18 | — | — | EP | disclosed |
| EP-0988295-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-29 | — | — | EP | disclosed |
| CN-1223659-A | Fused imidazopyridine derivatives as antihyperlipidemic agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-21 | — | — | CN | disclosed |
| WO-1999031060-A2 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES AS CYTOSTATICS AND IMMUNESUPPRESSANTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| EP-0915888-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | Takeda Chemical Industries, Ltd. (JP) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998057940-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
| US-5767131-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, INHIBITION OF CHOLESTEROL SYNTHESIS, LOWERING OF INTRAOCULAR PRESSURE; ALPHA-ADRENERGIC RECEPTOR DISEASES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
| WO-1994022829-A2 | DIHYDROPYRIDINES AND NEW USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-10-13 | — | — | WO | disclosed |
| US-3995045-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194296-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | FAAH, FAAH2, FFAR3 | SIGMAR1 270/4885MEN1 4240/4885TP53 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.